Search Results - "Akhade, Amol"

To Give or Not to Give Adjuvant Chemotherapy in Breast Cancer? Can CanAssist Breast Assist? by Akhade, Amol, Mathew, Aju

Get full text

Geriatric oncology in LMICs: it is time to mature by Akhade, Amol, Verduzco-Aguirre, Haydee, Gyawali, Bishal

Get full text

CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner? by Akhade, Amol, Van Wambeke, Simon, Gyawali, Bishal

“…CDK4/6 inhibitors have become the mainstay of treatment for patients with advanced hormone receptor positive and Human Epidermal Receptor -2 [ HER-2 ] negative…”
Get full text

Highlights from Choosing Wisely 2022 for Resource Limited Settings: Reducing Low Value Cancer Care for Sustainability conference, 17th-18th September, Mumbai, India by Akhade, Amol, Gyawali, Bishal, Sullivan, Richard, Sirohi, Bhawna

“…The 'Choosing Wisely 2022' conference, organised by the ecancer foundation, was held at the Tata Memorial Hospital, Mumbai, India, on 17 and 18 September. It…”
Get full text

Could We Have Improved on ADAURA? Refining Global Research Practices to Reduce Cancer Care Disparities by West, Howard (Jack), Akhade, Amol, Gyawali, Bishal

“…ADAURA was a positive trial, but could changes have improved it and reduced global care disparities?…”
Get full text

Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC) by Parikh, Purvish M., Vora, Amish, Yadav, Rajan, Kapoor, Akhil, Sahoo, Tarini, Rajappa, Senthil, Kanakashetty, Govind Babu, Krishna, M. Vamshi, Biswas, Ghanashyam, Bahl, Ankur, Ghadyalpatil, Nikhil, Raja, Thirumalairaj, Bajpai, Jyoti, Akhade, Amol, Singh, Randeep, Aggarwal, Shyam, Basade, Maheboob, Advani, S.H.

“…It is still not possible for all patients with early breast cancer to be cured. Even when they respond well to initial therapy, there exists a substantial risk…”
Get full text

Cancer research in lower- and middle-income countries (LMICs): How can we improve? by Akhade, Amol

Get full text

Global consequences of the US FDA's accelerated approval of cancer drugs by Akhade, Amol, Sirohi, Bhawna, Gyawali, Bishal

“…Up to a third of cancer drugs receiving accelerated approval that have not improved the primary endpoint in confirmatory trials remain on market.4 Because many…”
Get full text

Pembrolizumab Weight-Based Dosing: Conviction and Lacunae in Adopting a Cost-Saving Approach—A Survey Report by Patel, Amol, Akhade, Amol

“…Abstract Introduction Use of immunotherapy drugs has increased leaps and bounds in the last decade with promising results in some of the cancers. The use is…”
Get full text

Pembrolizumab weight based dosing – A call for policy change by Patel, Amol, Akhade, Amol, Parikh, Purvish, Sharma, Atul, Malhotra, Hemant, Prabhash, Kumar, Babu, Govind, Noronha, Vanita, Batra, Ullas, Mehta, Prashant, Gupta, Vineet Govinda, Radhakrishnan, Venkatraman, Boya, Rakesh Reddy, Biswas, Bivas

Get full text

Arsenic Trioxide (ATO) as Induction Therapy Achieves Early Complete Cytogenetic Remission In Acute Promyelocytic Leukemia (APL) by Menon, Hari, Akhade, Amol, Sengar, Manju, Amare, Pratibha, Subramanian, P., Nair, Reena, Chougule, Anuradha

“…Abstract 4350 All Trans Retinoic Acid (ATRA) with chemotherapy, though an effective induction therapy for newly diagnosed APL, is associated with significant…”
Get full text